Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.63+0.09 (+1.19%)
Close on Nov 18, 2026Market cap $44.12MP/E –Yield –
Xilio Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Xilio Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$31.37M. For fiscal 2025 it was -$41.98M. The highest annual figure on record is -$41.98M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$41.98M | – |
| FY2024 | Dec 31, 2024 | -$60.58M | – |
| FY2023 | Dec 31, 2023 | -$79.13M | – |
| FY2022 | Dec 31, 2022 | -$89.15M | – |
| FY2021 | Dec 31, 2021 | -$75.04M | – |
| FY2020 | Dec 31, 2020 | -$54.56M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.49M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.13M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.21M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.55M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.60M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.62M | – |
See a number that looks wrong?